Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Total Liabilities (2016 - 2025)

iBio (IBIO) has disclosed Total Liabilities for 15 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities changed 0.4% to $7.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.8 million, a 0.4% change, with the full-year FY2025 number at $8.3 million, up 12.08% from a year prior.
  • Total Liabilities was $7.8 million for Q4 2025 at iBio, down from $8.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $43.2 million in Q3 2021 to a low of $6.8 million in Q3 2024.
  • A 5-year average of $23.9 million and a median of $25.6 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: tumbled 72.36% in 2024, then grew 20.01% in 2025.
  • iBio's Total Liabilities stood at $35.8 million in 2021, then decreased by 8.01% to $33.0 million in 2022, then decreased by 24.72% to $24.8 million in 2023, then tumbled by 68.57% to $7.8 million in 2024, then rose by 0.4% to $7.8 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Total Liabilities are $7.8 million (Q4 2025), $8.1 million (Q3 2025), and $8.3 million (Q2 2025).